Press release
Hepatitis B Virus Infection Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, and Companies by DelveInsight
Hepatitis B Virus Infection companies include Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, more.(Albany, USA) DelveInsight, "Hepatitis B Virus Infection Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis B Virus Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hepatitis B Virus Infection Pipeline Report
* July 2024:- GlaxoSmithKline- A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment. This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with Human Immunodeficiency Virus (HIV)/Hepatitis B Virus (HBV) co-infection.
* July 2024:- Gilead Sciences- A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection. The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
* DelveInsight's Hepatitis B Virus Infection pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Hepatitis B Virus Infection treatment.
* The leading companies working in the Hepatitis B Virus Infection Market include Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
* Promising Hepatitis B Virus Infection Pipeline Therapies in the various stages of development include BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.
Request a sample and discover the recent advances in Hepatitis B Virus Infection Treatment Drugs @ Hepatitis B Virus Infection Pipeline Report [https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
In the Hepatitis B Virus Infection pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis B Virus (HBV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Hepatitis B Virus Infection Overview
Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Hepatitis B virus is transmitted via percutaneous inoculation or through mucosal exposure with infectious bodily fluids. Oral-fecal transmission is possible but considerably rare.
Find out more about Hepatitis B Virus Infection Therapeutics Assessment @ Hepatitis B Virus Infection Drugs [https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hepatitis B Virus Infection Emerging Drugs Profile
* Bepirovirsen: GSK
* VIR 2218: Vir Biotechnology
* AB 729: Arbutus Biopharma
* AHB-137: Ausper Biopharma
Hepatitis B Virus Infection Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the Hepatitis B Virus Infection. The Hepatitis B Virus Infection companies which have their Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. phase III include GSK.
DelveInsight's Hepatitis B Virus Infection pipeline report covers around 90+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Hepatitis B Virus Infection Pipeline Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Learn more about the emerging Hepatitis B Virus Infection Pipeline Therapies @ Hepatitis B Virus Infection Clinical Trials Assessment [https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Hepatitis B Virus Infection Pipeline Report
* Coverage- Global
* Hepatitis B Virus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hepatitis B Virus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Hepatitis B Virus Infection Companies- Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
* Hepatitis B Virus Infection Pipeline Therapies- BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.
Dive deep into rich insights for new drugs for Hepatitis B Virus Infection Treatment, Visit @ Hepatitis B Virus Infection Treatment Market [https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
* Introduction
* Executive Summary
* Hepatitis B Virus Infection: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hepatitis B Virus Infection- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Bepirovirsen: GSK
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* VIR 2218: Vir Biotechnology
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AHB-137: Ausper Biopharma
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Hepatitis B Virus Infection Key Companies
* Hepatitis B Virus Infection Key Products
* Hepatitis B Virus Infection- Unmet Needs
* Hepatitis B Virus Infection- Market Drivers and Barriers
* Hepatitis B Virus Infection- Future Perspectives and Conclusion
* Hepatitis B Virus Infection Analyst Views
* Hepatitis B Virus Infection Key Companies
* Appendix
For further information on the Hepatitis B Virus Infection Pipeline therapeutics, reach out to Hepatitis B Virus Infection Clinical Trials [https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatitis-b-virus-infection-clinical-trials-2024-ema-pdma-fda-approvals-medication-therapies-moa-roa-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatitis B Virus Infection Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, and Companies by DelveInsight here
News-ID: 3684675 • Views: …
More Releases from ABNewswire
JK Concrete Contractor Fort Worth Celebrates Growth as Tarrant County's Trusted …
JK Concrete Contractor Fort Worth expands capacity serving more homeowners and businesses-concrete driveways, patios, foundations, decorative concrete, complete solutions for residential and commercial properties throughout Tarrant County. Located at 1100 W Cannon St, #241, Fort Worth, TX 76104, the company experiences significant growth from increasing demand for quality concrete work-Fort Worth neighborhoods needing reliable contractors, property owners tired of substandard installations, commercial clients requiring professional solutions. Call (469) 252-8309 for…
FloatField Launches AI-Powered Outbound Automation System to Transform B2B Lead …
United States - November 19, 2025 - FloatField, [http://floatfield.com/]an emerging innovator in sales technology, today announced the launch of its groundbreaking AI-powered outbound automation system designed specifically for B2B companies. The platform is engineered to help businesses generate consistent, sales-ready leads by leveraging advanced AI-driven scraping, enrichment, and personalized outreach-all in one unified system.
Revolutionizing Outbound Prospecting
Traditional outbound prospecting has long been plagued by inefficiencies, high costs, and the need for…
Marketing Expert Reveals 15 "Cheat Code" Growth Strategies Most Businesses Are M …
Digital marketing strategist Tony Hayes releases comprehensive newsletter edition exposing unconventional growth tactics that bypass traditional methods. The latest Daily Growth Signals edition includes detailed implementation checklists for strategies ranging from "parasite SEO" that outranks company websites to AI-powered side hustles generating $2,035 daily, plus critical updates on Meta's algorithm changes affecting Facebook advertising.
CHON BURI, THAILAND - November 19, 2025 - Digital marketing strategist Tony Hayes has released his latest…
Why TMR Keyboards Are the Best Gaming Keyboards Available Now
TMR keyboards use advanced Tunnel Magnetoresistance sensors for higher sensitivity, lower power use, and more consistent performance than Hall Effect keyboards as reported by HLPLANET. Early models from MonsGeek, Womier, and Keychron are available, offering hot-swappable switches, various layouts, and wired/wireless options.
After a year dominated by Hall Effect mechanical keyboards, a new category of TMR-based keyboards [https://tmrkeyboard.com/] is starting to appear. These devices use Tunnel Magnetoresistance (TMR) sensors instead of…
More Releases for Vir
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
The influenza A market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM influenza A market size from 2020 to 2034. The report also covers current influenza A treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are…
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years.
DelveInsight has launched a new report on "Influenza A - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States,…
Investigation for NASDAQ: VIR Investors over possible Wrongdoing at Vir Biotechn …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Vir Biotechnology, Inc.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vir Biotechnology directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Francisco, CA based…
SOFTWARE-DEFINED NETWORKING AND NETWORK FUTUALIZATION MARKET knowNCTION VIR indu …
“The SDN and NFV is picking up noticeable quality because of the developing mechanical progressions in systems administration and server farm union. SDN is a momentous systems administration design, which is ready to totally alter the current systems administration and server farm foundation. The SDN building structure is set to reclassify the systems administration framework to meet the developing number of system clients devouring a high data transfer capacity. With…
Investigation announced for Investors in shares of Vir Biotechnology, Inc. (NASD …
Vir Biotechnology, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Vir Biotechnology, Inc. regarding its business, its prospects and its operations were materially false…
Global Balancing Valves Market 2017 - IMI Hydronic, Danfoss, Frese A/S, Caleffi, …
"A balancing valve is a measurement and regulation device. Balancing valves are used in pressurized piping applications, such as HVAC and gas movement applications. The main purpose of a balancing valve is generally to create a consistent output pressure to a system from an inconsistent input pressure from a different system."
Scope of the Report:
This report focuses on the Balancing Valves in Global market, especially in North America, Europe and Asia-Pacific,…
